Pneumagen has announced the publication of phase 2 data showing its antiviral therapy, Neumifil, significantly reduced ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting ...

Cidara Therapeutics has reported encouraging top-line outcomes from the Phase IIb NAVIGATE trial of the investigational drug-Fc conjugate (DFC), CD388, for seasonal influenza prevention in healthy ...

Influenza continues to pose a significant global health burden, with seasonal outbreaks causing substantial morbidity and mortality. Current ...

Shares of Cidada Therapeutics doubled in value on Monday and jumped in after-hours trading as the biotech firm released ...

Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu ...

The antiviral baloxavir significantly reduced household transmission of influenza compared with placebo. The drug showed consistent effects across age groups, virus types, and countries, with no ...

The cost–effectiveness of antiviral therapies ranged from cost savings to more than US$130,000 per quality-adjusted life-year (QALY) for influenza treatment, from GB£9000 to more than £1 ...

Existing antivirals may be less effective against this H5N1 bird flu strain, and prevention measures, such as avoiding raw milk consumption and reducing exposure in dairy workers, maybe the most ...